Insights of Psoriatic Arthritis Pipeline Review H2 2016 and Therapeutic Development

Psoriatic Arthritis – Pipeline Review, H2 2016, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.


Pune, Maharashtra -- (SBWire) -- 02/01/2017 --Psoriatic Arthritis Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Psoriatic Arthritis therapeutics industry report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Browse more detail information about Psoriatic Arthritis market report at:

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Psoriatic Arthritis – Pipeline Review, H2 2016:
- 3SBio Inc.
- AbbVie Inc
- AbGenomics International, Inc.
- Alteogen Inc.
- Amgen Inc.
- Biocon Limited
- Bionovis SA
- Bristol-Myers Squibb Company
- Celgene Corporation
- Coherus BioSciences, Inc.
- Eli Lilly and Company
- Forward Pharma A/S
- Genor BioPharma Co Ltd

Get a PDF Sample of Psoriatic Arthritis Market Research Report at:

Drug Profiles of Included in Psoriatic Arthritis Therapeutics Development Market Report
And other drug profiles

Have any query? ask our expert @

Key Topics Covered:
2.Psoriatic Arthritis Overview
3.Psoriatic Arthritis Therapeutics Development
4.Pipeline Products for Psoriatic Arthritis - Overview
5.Pipeline Products for Psoriatic Arthritis - Comparative Analysis
6.Psoriatic Arthritis - Therapeutics under Development by Companies
7.Psoriatic Arthritis - Therapeutics under Investigation by Universities/Institutes
8.Psoriatic Arthritis Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Psoriatic Arthritis - Products under Development by Companies
13.Psoriatic Arthritis - Products under Investigation by Universities/Institutes
14.Psoriatic Arthritis - Companies Involved in Therapeutics Development
15.Psoriatic Arthritis Drug Profiles
16.Psoriatic Arthritis Dormant Projects
17.Psoriatic Arthritis Discontinued Products
18.Psoriatic Arthritis Featured News & Press Releases
And Continue…

Get Discount on Psoriatic Arthritis Market Research Report at:

List of Figures
- Number of Products under Development for Psoriatic Arthritis, H2 2016
- Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Comparative Analysis by Late Stage Development, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Number of Products by Top 10 Targets, H2 2016

About Absolute Report
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Media Relations Contact

Ameya Pingaley
Absolute Reports

View this press release online at: